Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.

@article{Eisbruch2001RadiationCW,
  title={Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.},
  author={Avraham Eisbruch and Donna S. Shewach and Carol R. Bradford and J F Littles and Theodoros Teknos and Douglas B. Chepeha and Lawrence J. Marentette and Jeffrey E. Terrell and Norman D. Hogikyan and Laura Ann Dawson and Susan C Urba and G T Wolf and Theodore Steven Lawrence},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2001},
  volume={19 3},
  pages={792-9}
}
PURPOSE To examine the feasibility and dose-limiting toxicity (DLT) of once-weekly gemcitabine at doses predicted in preclinical studies to produce radiosensitization, concurrent with a standard course of radiation for locally advanced head and neck cancer. Tumor incorporation of gemcitabine triphosphate (dFdCTP) was measured to assess whether adequate concentrations were achieved at each dose level. PATIENTS AND METHODS Twenty-nine patients with unresectable head and neck cancer received a… CONTINUE READING